HILLEVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.64 USD | -1.45% |
|
-1.16% | -15.02% |
| 05-09 | HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-05 | Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 596.3 | 746.6 | 647.6 | - | - |
| Enterprise Value (EV) 1 | 596.3 | 468.3 | 647.6 | 647.6 | 647.6 |
| P/E ratio | -2.84 x | -5.28 x | -4.49 x | -4.13 x | -3.81 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 207 x |
| EV / Revenue | - | - | - | - | 207 x |
| EV / EBITDA | -9.16 x | -5.62 x | -3.99 x | -3.79 x | -3.39 x |
| EV / FCF | -9.03 x | -7.65 x | -4.01 x | -3.96 x | -3.4 x |
| FCF Yield | -11.1% | -13.1% | -24.9% | -25.2% | -29.4% |
| Price to Book | 1.7 x | 2.88 x | 3.13 x | 3.27 x | 3.77 x |
| Nbr of stocks (in thousands) | 35,644 | 46,516 | 47,475 | - | - |
| Reference price 2 | 16.73 | 16.05 | 13.64 | 13.64 | 13.64 |
| Announcement Date | 17/03/23 | 20/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 3.125 |
| EBITDA 1 | - | -65.11 | -132.9 | -162.3 | -170.7 | -191.3 |
| EBIT 1 | - | -65.11 | -133.3 | -168.7 | -199.4 | -239.9 |
| Operating Margin | - | - | - | - | - | -7,677.84% |
| Earnings before Tax (EBT) 1 | - | -159.8 | -123.6 | -159.3 | -191.8 | -233.2 |
| Net income 1 | -102.4 | -159.8 | -123.6 | -162.2 | -187.5 | -226.1 |
| Net margin | - | - | - | - | - | -7,235.04% |
| EPS 2 | -30.64 | -5.890 | -3.040 | -3.035 | -3.306 | -3.578 |
| Free Cash Flow 1 | - | -66 | -97.53 | -161.4 | -163.5 | -190.7 |
| FCF margin | - | - | - | - | - | -6,101.76% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 28/02/22 | 17/03/23 | 20/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -11.31 | -12.81 | -17.89 | -23.1 | -28.96 | -30.08 | -33.57 | -39.41 | - | - | - | - | - | - |
| EBIT 1 | -11.31 | -12.81 | -17.89 | -23.1 | -28.96 | -30.18 | -33.91 | -40.29 | -49.8 | -43.33 | -39.82 | -38.57 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -67.89 | -53.93 | -16.8 | -21.19 | -26.89 | -27.9 | -31.82 | -36.96 | -46.83 | -39.81 | -37.59 | -37.05 | - | - |
| Net income 1 | -67.89 | -53.93 | -16.8 | -21.19 | -26.89 | -27.9 | -31.82 | -36.96 | -46.83 | -39.81 | -37.59 | -37.05 | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -10.06 | -2.030 | -0.4500 | -0.5600 | -0.7100 | -0.7400 | -0.8100 | -0.7800 | -0.9700 | -0.8033 | -0.7036 | -0.6732 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 08/06/22 | 10/08/22 | 10/11/22 | 17/03/23 | 12/05/23 | 14/08/23 | 09/11/23 | 20/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | 278 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -66 | -97.5 | -161 | -163 | -191 |
| ROE (net income / shareholders' equity) | - | - | -46.4% | -63% | -70.7% | -76% |
| ROA (Net income/ Total Assets) | - | -71.9% | -37.4% | -47.2% | -51.7% | -55.8% |
| Assets 1 | - | 222.2 | 330.8 | 343.6 | 362.7 | 405.2 |
| Book Value Per Share 2 | - | 9.840 | 5.570 | 4.360 | 4.170 | 3.620 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 10.7 | 2 | 6.5 | 6.5 |
| Capex / Sales | - | - | - | - | - | 208.1% |
| Announcement Date | 28/02/22 | 17/03/23 | 20/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.64
USD
Average target price
29
USD
Spread / Average Target
+112.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.02% | 648M | |
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +45.09% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
- Stock Market
- Equities
- HLVX Stock
- Financials HilleVax, Inc.
